Tetrahydrocannabinolic Acid Reduces Nausea-induced Conditioned Gaping in Rats and Vomiting in Suncus Murinus
Overview
Authors
Affiliations
Background And Purpose: We evaluated the anti-emetic and anti-nausea properties of the acid precursor of Δ(9) -tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), and determined its mechanism of action in these animal models.
Experimental Approach: We investigated the effect of THCA on lithium chloride- (LiCl) induced conditioned gaping (nausea-induced behaviour) to a flavour, and context (a model of anticipatory nausea) in rats, and on LiCl-induced vomiting in Suncus murinus. Furthermore, we investigated THCA's ability to induce hypothermia and suppress locomotion [rodent tasks to assess cannabinoid1 (CB1 ) receptor agonist-like activity], and measured plasma and brain THCA and THC levels. We also determined whether THCA's effect could be blocked by pretreatment with SR141716 (SR, a CB1 receptor antagonist).
Key Results: In rats, THCA (0.05 and/or 0.5 mg·kg(-1) ) suppressed LiCl-induced conditioned gaping to a flavour and context; the latter effect blocked by the CB1 receptor antagonist, SR, but not by the 5-hydroxytryptamine-1A receptor antagonist, WAY100635. In S. murinus, THCA (0.05 and 0.5 mg·kg(-1) ) reduced LiCl-induced vomiting, an effect that was reversed with SR. A comparatively low dose of THC (0.05 mg·kg(-1) ) did not suppress conditioned gaping to a LiCl-paired flavour or context. THCA did not induce hypothermia or reduce locomotion, indicating non-CB1 agonist-like effects. THCA, but not THC was detected in plasma samples.
Conclusions And Implications: THCA potently reduced conditioned gaping in rats and vomiting in S. murinus, effects that were blocked by SR. These data suggest that THCA may be a more potent alternative to THC in the treatment of nausea and vomiting.
Kim E, Park S, Kinney C, Olejar K, Corredor-Perilla I Sci Rep. 2024; 14(1):16411.
PMID: 39013926 PMC: 11252385. DOI: 10.1038/s41598-024-66420-3.
Cannabinol: History, Syntheses, and Biological Profile of the Greatest "Minor" Cannabinoid.
Maioli C, Mattoteia D, Amin H, Minassi A, Caprioglio D Plants (Basel). 2022; 11(21).
PMID: 36365350 PMC: 9658060. DOI: 10.3390/plants11212896.
Differentiating Cannabis Products: Drugs, Food, and Supplements.
Salehi A, Puchalski K, Shokoohinia Y, Zolfaghari B, Asgary S Front Pharmacol. 2022; 13:906038.
PMID: 35833025 PMC: 9271575. DOI: 10.3389/fphar.2022.906038.
The Medicinal Natural Products of Linn.: A Review.
Odieka A, Obuzor G, Oyedeji O, Gondwe M, Hosu Y, Oyedeji A Molecules. 2022; 27(5).
PMID: 35268790 PMC: 8911748. DOI: 10.3390/molecules27051689.
Cannabidiol (CBD) in Cancer Management.
OBrien K Cancers (Basel). 2022; 14(4).
PMID: 35205633 PMC: 8869992. DOI: 10.3390/cancers14040885.